Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intraveneuze Lidocaïne-infusie bij Lumbale Fusiechirurgie

23 september 2026 bijgewerkt door: Ankara City Hospital Bilkent

Effect van intraveneuze intraoperatieve lidocaïne-infusie op postoperatieve opioïdeconsumptie en herstel na lumbale fusie-operatie: Een gerandomiseerde gecontroleerde studie

Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.

This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.

The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.

Studie Overzicht

Toestand

Werving

Gedetailleerde beschrijving

Lumbar fusion surgery is frequently associated with significant postoperative pain and often requires high doses of opioid analgesics during the perioperative period. Opioid administration may lead to several adverse effects including postoperative nausea and vomiting, sedation, respiratory depression, and delayed recovery. Therefore, multimodal analgesia strategies are increasingly used to improve postoperative pain control and reduce opioid requirements.

Intravenous lidocaine infusion has gained attention as an adjunct component of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. Previous clinical studies have suggested that perioperative systemic lidocaine may reduce postoperative pain intensity, decrease opioid consumption, and improve recovery after surgery. However, evidence regarding its effectiveness in patients undergoing lumbar fusion surgery remains limited.

This prospective, randomized, placebo-controlled study will include adult patients aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for elective lumbar fusion surgery. Participants will be randomly allocated into two groups. Patients in the lidocaine group will receive an intravenous lidocaine bolus followed by continuous lidocaine infusion during surgery, whereas patients in the control group will receive an equivalent volume of normal saline infusion. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Postoperative pain will be assessed using the Numerical Rating Scale (NRS). Rescue analgesia will be administered when clinically indicated.

The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores at predefined time points, time to first rescue analgesic requirement, postoperative nausea and vomiting incidence, quality of recovery measured by QoR-15, post-anesthesia care unit length of stay, time to mobilization, and hospital length of stay.

In addition, inflammatory and oxidative stress responses associated with surgery and lidocaine administration will be evaluated. Blood samples will be collected preoperatively and at 6 and 24 hours postoperatively to measure interleukin-6 (IL-6) levels and markers of thiol-disulfide homeostasis.

Studietype

Ingrijpend

Inschrijving (Geschat)

110

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age ≥18 years
  • Scheduled for elective lumbar fusion surgery under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Ability to provide written informed consent

Exclusion Criteria:

  • Refusal to participate in the study
  • ASA physical status ≥IV
  • Body mass index >35 kg/m²
  • Known allergy or hypersensitivity to lidocaine or study medications
  • Severe cardiac, hepatic, or renal disease
  • Pregnancy
  • Neurological disorders affecting pain assessment
  • Chronic opioid use
  • Use of opioids or antiemetic drugs before surgery
  • Inability to cooperate with postoperative assessments

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Lidocaine Infusion

Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg/kg/h throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia.

Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

Placebo-vergelijker: Placebo (Normal Saline)

Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia.

An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cumulative postoperative opioid consumption within the first 24 hours after surgery
Tijdsspanne: 0 to 24 hours after surgery

Cumulative opioid consumption during the first 24 postoperative hours will be evaluated. Rescue analgesia will be administered as intravenous tramadol (100 mg) when the Numerical Rating Scale (NRS) pain score is ≥4. The cumulative tramadol dose administered during this period will be recorded in milligrams (mg).

0 to 24 hours after surgery

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Intraoperative remifentanil consumption
Tijdsspanne: From induction of anesthesia to the end of surgery

Cumulative remifentanil consumption during surgery will be recorded in micrograms (µg).

From induction of anesthesia to the end of surgery
Postoperative pain intensity
Tijdsspanne: At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery

Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain).

At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
Time to first rescue analgesic requirement
Tijdsspanne: Within the first 24 hours after surgery

Time from the end of surgery to the first administration of rescue intravenous tramadol will be recorded.

Within the first 24 hours after surgery
Quality of recovery
Tijdsspanne: Preoperative baseline and 24 hours after surgery

Quality of recovery will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire, a validated patient-reported outcome measure assessing postoperative recovery. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery.

Preoperative baseline and 24 hours after surgery
Postoperative nausea and vomiting incidence
Tijdsspanne: 0-24 hours after surgery

The incidence of postoperative nausea and/or vomiting and the requirement for rescue antiemetic treatment will be recorded.

0-24 hours after surgery
Post-anesthesia care unit length of stay
Tijdsspanne: Immediate postoperative period (up to 24 hours after surgery)

Duration of stay in the post-anesthesia care unit will be recorded in minutes.

Immediate postoperative period (up to 24 hours after surgery)
Time to mobilization
Tijdsspanne: Up to 24 hours after surgery

Time from the end of surgery to the first mobilization will be recorded.

Up to 24 hours after surgery
Serum interleukin-6 (IL-6) levels
Tijdsspanne: Preoperatively and at 6 and 24 hours after surgery

Serum interleukin-6 (IL-6) levels will be measured to evaluate the inflammatory response.

Preoperatively and at 6 and 24 hours after surgery

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Thiol-disulfide homeostasis parameters
Tijdsspanne: Preoperatively and at 6 and 24 hours after surgery

Native thiol, total thiol, and disulfide levels will be measured to evaluate oxidative stress and thiol-disulfide homeostasis.

Preoperatively and at 6 and 24 hours after surgery
Length of hospital stay
Tijdsspanne: Through hospital discharge, an average of 5 days

Total duration of hospitalization will be recorded in days.

Through hospital discharge, an average of 5 days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Gokhan Erdem, MD, PhD, Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 april 2026

Primaire voltooiing (Geschat)

1 januari 2027

Studie voltooiing (Geschat)

1 maart 2027

Studieregistratiedata

Eerst ingediend

16 maart 2026

Eerst ingediend dat voldeed aan de QC-criteria

19 maart 2026

Eerst geplaatst (Werkelijk)

23 maart 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

23 september 2026

Laatst geverifieerd

1 maart 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

No plan to share individual participant data.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren